In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.

Candida is the most common fungal pathogen of humans worldwide and has become a major clinical problem because of the growing number of immunocompromised patients, who are susceptible to infection. Moreover, the number of available antifungals is limited, and antifungal-resistant Candida strains are...

Full description

Bibliographic Details
Main Authors: Sarah Sze Wah Wong, Richard Yi Tsun Kao, Kwok Yong Yuen, Yu Wang, Dan Yang, Lakshman Perera Samaranayake, Chaminda Jayampath Seneviratne
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3899067?pdf=render
id doaj-0941592439104178b718c83e6da4545f
record_format Article
spelling doaj-0941592439104178b718c83e6da4545f2020-11-25T01:26:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8583610.1371/journal.pone.0085836In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.Sarah Sze Wah WongRichard Yi Tsun KaoKwok Yong YuenYu WangDan YangLakshman Perera SamaranayakeChaminda Jayampath SeneviratneCandida is the most common fungal pathogen of humans worldwide and has become a major clinical problem because of the growing number of immunocompromised patients, who are susceptible to infection. Moreover, the number of available antifungals is limited, and antifungal-resistant Candida strains are emerging. New and effective antifungals are therefore urgently needed. Here, we discovered a small molecule with activity against Candida spp. both in vitro and in vivo. We screened a library of 50,240 small molecules for inhibitors of yeast-to-hypha transition, a major virulence attribute of Candida albicans. This screening identified 20 active compounds. Further examination of the in vitro antifungal and anti-biofilm properties of these compounds, using a range of Candida spp., led to the discovery of SM21, a highly potent antifungal molecule (minimum inhibitory concentration (MIC) 0.2-1.6 µg/ml). In vitro, SM21 was toxic to fungi but not to various human cell lines or bacterial species and was active against Candida isolates that are resistant to existing antifungal agents. Moreover, SM21 was relatively more effective against biofilms of Candida spp. than the current antifungal agents. In vivo, SM21 prevented the death of mice in a systemic candidiasis model and was also more effective than the common antifungal nystatin at reducing the extent of tongue lesions in a mouse model of oral candidiasis. Propidium iodide uptake assay showed that SM21 affected the integrity of the cell membrane. Taken together, our results indicate that SM21 has the potential to be developed as a novel antifungal agent for clinical use.http://europepmc.org/articles/PMC3899067?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Sarah Sze Wah Wong
Richard Yi Tsun Kao
Kwok Yong Yuen
Yu Wang
Dan Yang
Lakshman Perera Samaranayake
Chaminda Jayampath Seneviratne
spellingShingle Sarah Sze Wah Wong
Richard Yi Tsun Kao
Kwok Yong Yuen
Yu Wang
Dan Yang
Lakshman Perera Samaranayake
Chaminda Jayampath Seneviratne
In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.
PLoS ONE
author_facet Sarah Sze Wah Wong
Richard Yi Tsun Kao
Kwok Yong Yuen
Yu Wang
Dan Yang
Lakshman Perera Samaranayake
Chaminda Jayampath Seneviratne
author_sort Sarah Sze Wah Wong
title In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.
title_short In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.
title_full In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.
title_fullStr In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.
title_full_unstemmed In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.
title_sort in vitro and in vivo activity of a novel antifungal small molecule against candida infections.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Candida is the most common fungal pathogen of humans worldwide and has become a major clinical problem because of the growing number of immunocompromised patients, who are susceptible to infection. Moreover, the number of available antifungals is limited, and antifungal-resistant Candida strains are emerging. New and effective antifungals are therefore urgently needed. Here, we discovered a small molecule with activity against Candida spp. both in vitro and in vivo. We screened a library of 50,240 small molecules for inhibitors of yeast-to-hypha transition, a major virulence attribute of Candida albicans. This screening identified 20 active compounds. Further examination of the in vitro antifungal and anti-biofilm properties of these compounds, using a range of Candida spp., led to the discovery of SM21, a highly potent antifungal molecule (minimum inhibitory concentration (MIC) 0.2-1.6 µg/ml). In vitro, SM21 was toxic to fungi but not to various human cell lines or bacterial species and was active against Candida isolates that are resistant to existing antifungal agents. Moreover, SM21 was relatively more effective against biofilms of Candida spp. than the current antifungal agents. In vivo, SM21 prevented the death of mice in a systemic candidiasis model and was also more effective than the common antifungal nystatin at reducing the extent of tongue lesions in a mouse model of oral candidiasis. Propidium iodide uptake assay showed that SM21 affected the integrity of the cell membrane. Taken together, our results indicate that SM21 has the potential to be developed as a novel antifungal agent for clinical use.
url http://europepmc.org/articles/PMC3899067?pdf=render
work_keys_str_mv AT sarahszewahwong invitroandinvivoactivityofanovelantifungalsmallmoleculeagainstcandidainfections
AT richardyitsunkao invitroandinvivoactivityofanovelantifungalsmallmoleculeagainstcandidainfections
AT kwokyongyuen invitroandinvivoactivityofanovelantifungalsmallmoleculeagainstcandidainfections
AT yuwang invitroandinvivoactivityofanovelantifungalsmallmoleculeagainstcandidainfections
AT danyang invitroandinvivoactivityofanovelantifungalsmallmoleculeagainstcandidainfections
AT lakshmanpererasamaranayake invitroandinvivoactivityofanovelantifungalsmallmoleculeagainstcandidainfections
AT chamindajayampathseneviratne invitroandinvivoactivityofanovelantifungalsmallmoleculeagainstcandidainfections
_version_ 1725109461905833984